Anika Therapeutics (ANIK) Misses Q2 EPS by 5c

Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of ($0.13), $0.05 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $28.22 million versus the consensus estimate of $28.15 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• JPMorgan Upgrades Diploma Plc. (DPLM:LN) to Overweight
• ICICI Securities Resumes Dalmia Bharat Ltd (DALBHARA:IN) at Add (2)
• Nomura/Instinet Reiterates Buy Rating on Samsung Electronics Co Ltd. (005930:KS) (SSNLF)